Formulary Watch Newsletter

To view this email as a web page, click here.

Novartis defends data on its $2.1 million drug

Novartis is defending its actions in FDA’s review of its $2.1 million drug for a rare pediatric disease.

GAO: Generic drug approvals too slow

FDA needs to speed up generic drug application reviews, a new report said.

FDA adds warning to Xeljanz

FDA is adding an important new Boxed Warning to the higher-dose version of the drug.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.